vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Planet Labs PBC (PL). Click either name above to swap in a different company.

Planet Labs PBC is the larger business by last-quarter revenue ($81.3M vs $77.6M, roughly 1.0× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -72.8%, a 63.2% gap on every dollar of revenue. On growth, Planet Labs PBC posted the faster year-over-year revenue change (32.6% vs -16.8%). Over the past eight quarters, Planet Labs PBC's revenue compounded faster (17.5% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Planet Labs PBC, known as "Planet.", is a publicly traded American Earth imaging company based in San Francisco, California. Their goal is to image the entirety of the Earth daily to monitor changes and pinpoint trends.

BIOX vs PL — Head-to-Head

Bigger by revenue
PL
PL
1.0× larger
PL
$81.3M
$77.6M
BIOX
Growing faster (revenue YoY)
PL
PL
+49.4% gap
PL
32.6%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
63.2% more per $
BIOX
-9.6%
-72.8%
PL
Faster 2-yr revenue CAGR
PL
PL
Annualised
PL
17.5%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BIOX
BIOX
PL
PL
Revenue
$77.6M
$81.3M
Net Profit
$-7.4M
$-59.2M
Gross Margin
46.8%
57.3%
Operating Margin
9.3%
-22.6%
Net Margin
-9.6%
-72.8%
Revenue YoY
-16.8%
32.6%
Net Profit YoY
-20.2%
-194.7%
EPS (diluted)
$-0.12
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
PL
PL
Q4 25
$81.3M
Q3 25
$77.6M
$73.4M
Q2 25
$66.3M
Q1 25
$60.6M
$61.6M
Q4 24
$98.8M
$61.3M
Q3 24
$93.3M
$61.1M
Q2 24
$60.4M
Q1 24
$84.0M
$58.9M
Net Profit
BIOX
BIOX
PL
PL
Q4 25
$-59.2M
Q3 25
$-7.4M
$-22.6M
Q2 25
$-12.6M
Q1 25
$-1.6M
$-35.2M
Q4 24
$605.2K
$-20.1M
Q3 24
$-6.2M
$-38.7M
Q2 24
$-29.3M
Q1 24
$9.8M
$-30.1M
Gross Margin
BIOX
BIOX
PL
PL
Q4 25
57.3%
Q3 25
46.8%
57.6%
Q2 25
55.2%
Q1 25
39.4%
62.1%
Q4 24
42.0%
61.2%
Q3 24
40.2%
52.9%
Q2 24
52.4%
Q1 24
50.8%
55.2%
Operating Margin
BIOX
BIOX
PL
PL
Q4 25
-22.6%
Q3 25
9.3%
-24.5%
Q2 25
-34.4%
Q1 25
1.5%
-31.5%
Q4 24
14.5%
-36.9%
Q3 24
2.5%
-64.8%
Q2 24
-57.2%
Q1 24
15.7%
-57.6%
Net Margin
BIOX
BIOX
PL
PL
Q4 25
-72.8%
Q3 25
-9.6%
-30.8%
Q2 25
-19.1%
Q1 25
-2.6%
-57.1%
Q4 24
0.6%
-32.8%
Q3 24
-6.6%
-63.3%
Q2 24
-48.5%
Q1 24
11.6%
-51.1%
EPS (diluted)
BIOX
BIOX
PL
PL
Q4 25
$-0.19
Q3 25
$-0.12
$-0.07
Q2 25
$-0.04
Q1 25
$-0.02
$-0.12
Q4 24
$0.00
$-0.07
Q3 24
$-0.10
$-0.13
Q2 24
$-0.10
Q1 24
$0.14
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
PL
PL
Cash + ST InvestmentsLiquidity on hand
$15.5M
$443.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$349.6M
Total Assets
$734.9M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
PL
PL
Q4 25
$443.3M
Q3 25
$15.5M
$181.1M
Q2 25
$133.5M
Q1 25
$38.5M
$118.0M
Q4 24
$29.2M
$139.0M
Q3 24
$32.3M
$148.3M
Q2 24
$107.4M
Q1 24
$16.4M
$83.9M
Stockholders' Equity
BIOX
BIOX
PL
PL
Q4 25
$349.6M
Q3 25
$288.3M
$435.7M
Q2 25
$444.8M
Q1 25
$345.0M
$441.3M
Q4 24
$346.3M
$464.6M
Q3 24
$346.0M
$473.2M
Q2 24
$500.3M
Q1 24
$348.5M
$518.0M
Total Assets
BIOX
BIOX
PL
PL
Q4 25
$1.1B
Q3 25
$734.9M
$696.4M
Q2 25
$658.4M
Q1 25
$798.2M
$633.8M
Q4 24
$835.2M
$630.8M
Q3 24
$827.3M
$658.4M
Q2 24
$674.6M
Q1 24
$836.1M
$702.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
PL
PL
Operating Cash FlowLast quarter
$14.4M
$28.6M
Free Cash FlowOCF − Capex
$1.9M
FCF MarginFCF / Revenue
2.3%
Capex IntensityCapex / Revenue
32.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$40.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
PL
PL
Q4 25
$28.6M
Q3 25
$14.4M
$67.8M
Q2 25
$17.3M
Q1 25
$23.3M
$-6.3M
Q4 24
$-5.4M
$4.1M
Q3 24
$5.2M
$-7.9M
Q2 24
$-4.3M
Q1 24
$-17.4M
$-6.8M
Free Cash Flow
BIOX
BIOX
PL
PL
Q4 25
$1.9M
Q3 25
$47.5M
Q2 25
$9.2M
Q1 25
$-17.9M
Q4 24
$-3.6M
Q3 24
$-23.0M
Q2 24
$-14.2M
Q1 24
$-15.7M
FCF Margin
BIOX
BIOX
PL
PL
Q4 25
2.3%
Q3 25
64.7%
Q2 25
13.9%
Q1 25
-29.1%
Q4 24
-5.8%
Q3 24
-37.6%
Q2 24
-23.6%
Q1 24
-26.7%
Capex Intensity
BIOX
BIOX
PL
PL
Q4 25
32.9%
Q3 25
27.6%
Q2 25
12.3%
Q1 25
18.9%
Q4 24
12.5%
Q3 24
24.8%
Q2 24
16.4%
Q1 24
15.1%
Cash Conversion
BIOX
BIOX
PL
PL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

PL
PL

Defense And Intelligence$49.4M61%
Civil Government$18.8M23%
Commercial$13.1M16%

Related Comparisons